The Patent Finder

Terms ending in 2035

BioAtla Inc.

Every in-force patent on BioAtla Inc.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 9,683,048Antibody Molecules to PD-1 and Uses Thereof
In force
 · High confidence
Novartis AGIn forceHigh confidence
US 9,815,898Antibody Molecules to PD-1 and Uses Thereof
In force
 · High confidence
Novartis AGIn forceHigh confidence
US 9,908,936Antibody Molecules to LAG-3 and Uses Thereof
In force
 · High confidence
Immutep S.A.S.In forceHigh confidence
US 12,252,535Antibody Molecules to LAG-3 and Uses Thereof
In force
 · High confidence
Immutep S.A.S.In forceHigh confidence
US 12,600,777Combination Therapies Comprising Antibody Molecules to LAG-3
In force
 · Low confidence
Novartis AGIn forceLow confidence
US 10,711,060Antibody Molecules to LAG-3 and Uses Thereof
In force
 · High confidence
Novartis AGIn forceHigh confidence
US 10,329,556Conditionally Active Biological Proteins
In force
 · High confidence
BioAtla, Inc.In forceHigh confidence
US 10,752,687Antibody Molecules to PD-1 and Uses Thereof
In force
 · High confidence
Novartis AGIn forceHigh confidence
US 9,988,452Antibody Molecules to PD-L1 and Uses Thereof
In force
 · High confidence
Novartis AGIn forceHigh confidence
9 of 9 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by BioAtla Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited